The administration of tamoxifen to patients with early stage breast cancer expressing the estrogen receptor (ER) significantly reduces tumor recurrence in many cases, but markers predictive of treatment failure have not been identified. Using gene expression profile analysis of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen only, we identified a novel biomarker that is predictive of tumor recurrence with an overall accuracy of 80%. This biomarker, consisting of a ratio of two genes, the homeobox gene HOXB13 and the interleukin 17B receptor gene, outperforms all existing biomarkers. Furthermore, ectopic expression of one of these genes, HOXB13, in MCF10A breast epithelial cells enhances HER1-and HER2- motility and invasion in vitro, and HOXB13 expression is increased in vivo in preinvasive and invasive primary breast cancers, including a subset of ER-negative tumors. The overall goals of the project are: 1) to validate the clinical utility of this novel two-gene expression biomarker to predict the clinical outcome in early stage breast cancer;and 2) to determine the role of HOXB13 in ER-positive and ER-negative breast cancer. Specifically, in Aims 1 and 2, we propose to validate the predictive utility of this biomarker in a cohort of women with ER positive breast cancer and in a cohort of women with ER-negative breast cancer. We will then, in the second parts of Aims 1 and 2, determine the role of HOXB13 in ER-mediated transcriptional activation and its effects on HER1- and HER2-mediated signaling in in vitro models of ER-positive and ER-negative breast cancer, respectively. Finally, in Aim 3, through genetic crosses between HOXB13 knockout mice and transgenic mice targeting expression of HER2/neu and cyclin D1, we propose to determine whether HOXB13 is necessary for the breast tumorigenesis in mouse models of ER-positive and -negative breast cancer.
In Aim 3, we also plan to characterize transgenic mice targeting expression of HOXB13. Accomplishment of these goals will improve identification of patients appropriate for alternative hormonal or chemotherapeutic regimens, and may open new avenues of research into the molecular mechanisms of resistance to tamoxifen.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA112021-05
Application #
7555617
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Forry, Suzanne L
Project Start
2005-03-11
Project End
2010-05-31
Budget Start
2009-02-01
Budget End
2010-05-31
Support Year
5
Fiscal Year
2009
Total Cost
$280,337
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Miles, Wayne O; Lembo, Antonio; Volorio, Angela et al. (2016) Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation. Cancer Res 76:7231-7241
Olsen, Lars; Campos, Benito; Winther, Ole et al. (2014) Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. BMC Med Genomics 7 Suppl 3:S2
Price, Jessica C; Pollock, Lana M; Rudd, Meghan L et al. (2014) Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A. PLoS One 8:e63313
Rudd, Meghan L; Mohamed, Hassan; Price, Jessica C et al. (2014) Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer 14:884
Shen, Keyue; Luk, Samantha; Hicks, Daniel F et al. (2014) Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays. Nat Commun 5:5662
Habel, Laurel A; Sakoda, Lori C; Achacoso, Ninah et al. (2013) HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res 15:R24
Sgroi, Dennis C; Carney, Erin; Zarrella, Elizabeth et al. (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036-42
Sgroi, Dennis C; Sestak, Ivana; Cuzick, Jack et al. (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067-1076
Le Gallo, Matthieu; O'Hara, Andrea J; Rudd, Meghan L et al. (2012) Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 44:1310-5
Imielinski, Marcin; Cha, Sangwon; Rejtar, Tomas et al. (2012) Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteomics 11:M111.014910

Showing the most recent 10 out of 31 publications